A paper entitled “Clinical effects of the enhanced external counterpulsation therapy in patients with ischemic chronic heart failure exacerbation COVID-19” has just been published in the European Heart Journal on 14 October 2021. The authors I Shashenkov, S.A. Gabrushenko, S.L. Babak and A.G. Mallavin have many years of experience with EECP therapy in Russia and have published on EECP therapy before. In this paper they concluded that “Enhanced external counterpulsation (EECP) therapy sustainably improves NYHA functional class and LVEF in patients with ischemic CHF exacerbation after COVID-19”. For more information go to https;//doi.org/10.1093/eurheartj/ehab724.0928.